19 Result(s)

Article

Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma

H Tilly, F Morschhauser, G Salles, R-O Casasnovas, P Feugier, T J Molina… in Leukemia (2013)

Article

The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab

Gene expression profiles have been associated with clinical outcome in patients with diffuse large B-cell lymphoma (DLBCL) treated with anthracycline-containing chemotherapy. Using Affymetrix HU133A microarray...

J-P Jais, C Haioun, T J Molina, D S Rickman, A de Reynies, F Berger… in Leukemia (2008)

Article

Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria

Since the initial description of splenic marginal zone lymphoma (SMZL) in 1992, an increasing number of publications have dealt with multiple aspects of SMZL diagnosis, molecular pathogenesis and treatment. Th...

E Matutes, D Oscier, C Montalban, F Berger, E Callet-Bauchu, A Dogan, P Felman… in Leukemia (2008)

Article

Analysis of BCL-6, CD95, PIM1, RHO/TTF and PAX5 mutations in splenic and nodal marginal zone B-cell lymphomas suggests a particular B-cell origin

A Traverse-Glehen, A Verney, L Baseggio, P Felman, E Callet-Bauchu… in Leukemia (2007)

Article

Rituximab therapy in malignant lymphoma

Rituximab is the first monoclonal antibody to have been registered for the treatment of B-cell lymphomas. Randomized studies haves demonstrated its activity in follicular lymphoma (FL), mantle cell lymphoma an...

B Coiffier in Oncogene (2007)

Article

Cytogenetic analysis delineates a spectrum of chromosomal changes that can distinguish non-MALT marginal zone B-cell lymphomas among mature B-cell entities: a description of 103 cases

The purpose of this study was to document the frequency and distribution of karyotypic changes present at diagnosis in 103 non-MALT marginal zone cell lymphoma (MZL) patients. This cytogenetic analysis of a la...

E Callet-Bauchu, L Baseggio, P Felman, A Traverse-Glehen, F Berger, D Morel… in Leukemia (2005)

Article

FcγRIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP+rituximab (R-CHOP)

S Camilleri-Broët, N Mounier, A Delmer, J Brière, O Casasnovas, L Cassard… in Leukemia (2004)

Article

Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma

Rituximab, an anti-CD20 monoclonal antibody, is increasingly used in the treatment of B-cell non-Hodgkin's lymphoma. Late-onset neutropenia in relation to rituximab has been recently described. In this report,...

B Lemieux, S Tartas, C Traulle, D Espinouse, C Thieblemont… in Bone Marrow Transplantation (2004)

Article

Autoimmune thrombocytopenic purpura after autologous stem cell transplantation

The pathogenesis of thrombocytopenia occurring after autologous stem cell transplantation (ASCT) remains unclear. Six cases of classical peripheral thrombocytopenia that developed after ASCT for non-Hodgkin's ...

O Hequet, G Salles, N Ketterer, D Espinouse, C Dumontet… in Bone Marrow Transplantation (2003)

Article

Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients

With the introduction of new drugs such as alpha-interferon (IFN) and purine analogs, the management of hairy cell leukemia (HCL) patients has changed. However, deoxycoformycin (DCF) produced higher complete r...

F Maloisel, L Benboubker, M Gardembas, B Coiffier, M Divine, C Sebban, M Blanc… in Leukemia (2003)

Article

Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma

High-dose melphalan (HDM) has been adopted as standard therapy in the treatment of multiple myeloma. This treatment is associated with non-selective cytotoxicity, causing oral mucositis as the major non-hemato...

C Thieblemont, C Dumontet, H Saad, N Roch, F Bouafia… in Bone Marrow Transplantation (2002)

Article

Identification and validation of seven genes, as potential markers, for the differential diagnosis of small B cell lymphomas (small lymphocytic lymphoma, marginal zone B cell lymphoma and mantle cell lymphoma) by cDNA macroarrays analysis

C Thieblemont, K Chettab, P Felman, E Callet-Bauchu, A Traverse-Glehen… in Leukemia (2002)

Article

Epileptic seizures after autologous peripheral blood progenitor infusion in a patient treated with high-dose chemotherapy for myeloma

Bone Marrow Transplantation (2002) 29, 544. doi:10.1038/sj.bmt.1703383

O Hequet, C Dumontet, A El Jaafari-Corbin, G Salles… in Bone Marrow Transplantation (2002)

Article

A prospective study of intensive induction therapy with high-dose consolidation in patients with aggressive non-Hodgkin's lymphoma and two or three adverse prognostic factors

Patients with nhl and two or three factors of the international prognostic index (ipi) have a poor prognosis. we performed a prospective trial of intensive induction therapy followed with high-dose consolidati...

C Dumontet, C Thieblemont, D Espinouse, F Bouafia, O Hequet, G Salles… in Leukemia (2000)

Article

Toxicities after peripheral blood progenitor cell transplantation for lymphoid malignancies: analysis of 300 cases in a single institution

Two hundred and seventy-seven consecutive patients with non-Hodgkin’s lymphoma (n = 207), Hodgkin’s disease (n = 27) and multiple myeloma (n = 43) were intensified from October 1989 until April 1997 and received ...

N Ketterer, A Sonet, C Dumontet, I Moullet, C Thieblemont… in Bone Marrow Transplantation (1999)

Article

Profiles and prognostic values of LDH isoenzymes in patients with non-Hodgkin’s lymphoma

Serum lactic dehydrogenase (LDH) is an important prognostic factor in patients with non-Hodgkin’s lymphoma (NHL). We have examined the LDH isoenzyme content in serum and CSF of patients with NHL, at diagnosis ...

C Dumontet, J Drai, J Bienvenu, E Neidhardt Berard, C Thieblemont, F Bouafia… in Leukemia (1999)

Article

Translocations involving the short arm of chromosome 17 in chronic B-lymphoid disorders: frequent occurrence of dicentric rearrangements and possible association with adverse outcome

Unbalanced translocations involving chromosome arm 17p, where the TP53 tumor suppressor gene localizes, are rarely described in chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL), but recent...

E Callet-Bauchu, G Salles, S Gazzo, C Poncet, D Morel, J Pagès, B Coiffier… in Leukemia (1999)

Article

Mantle cell lymphoma: a retrospective study of 121 cases

Mantle cell lymphoma (MCL) patients represent a difficult problem, sometimes to establish the diagnosis but mostly because of their refractoriness to standard lymphoma treatments. Which treatments to apply and...

H Samaha, C Dumontet, N Ketterer, I Moullet, C Thieblemont, F Bouafia… in Leukemia (1998)

Article

Reduced progression-free survival in elderly patients receiving intensification with autologous peripheral blood stem cell reinfusion for multiple myeloma

Between 1990 and 1997, 55 patients with high risk multiple myeloma underwent high-dose therapy with peripheral blood stem cell transplantation. Intensification consisted of high-dose L-PAM in 54 patients, and ...

C Dumontet, N Ketterer, D Espinouse, EM Neidhardt, I Moullet… in Bone Marrow Transplantation (1998)